Micetal

Flutrimazole

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micetal

Micetal is a specialized topical medication designed to treat superficial skin infections. It contains the sole active ingredient, Flutrimazole, which is categorized as an azole derivative within the broader class of Antifungal agents (antimycotics).

Property	Description
Active ingredient	Flutrimazole
Form	Cream, Solution, Spray
Pharmacological class	Azole Antifungal Agent
Common use	To eliminate superficial fungal infections
Origin	Synthetic compound

What Type of Medicine is Micetal (Flutrimazole)?

Micetal's identity is anchored by Flutrimazole, a synthetic compound that functions as a single-ingredient antifungal agent. This medicine is chemically recognized as an imidazole derivative and is listed under the Anatomical Therapeutic Chemical (ATC) code D01AC16 for dermatological antifungals. Its classification within the azole derivative group defines its powerful and targeted activity against a wide spectrum of common fungal species, including dermatophytes and yeasts. Flutrimazole is clinically recognized for its effective and focused activity against the organisms responsible for common ringworm infections and candidiasis.

How is Micetal Applied and What is its General Purpose?

Micetal is strictly intended for topical administration, meaning it is applied externally to the skin surface, ensuring its action is localized to the affected area. The medication is commonly supplied in several forms, including a cutaneous cream, a topical solution (liquid for skin use), and a cutaneous spray solution. The solution and spray forms are frequently chosen for application to larger or hair-covered areas, offering convenience over traditional creams in such cases.

The general therapeutic purpose of Micetal is the targeted elimination of superficial mycoses, which helps to resolve skin discomfort and stops the proliferation of the underlying infection. For example, it is typically used for conditions like athlete's foot (Tinea pedis). The medication achieves this through a specific mechanism: Flutrimazole prevents the fungal cell from producing ergosterol, a molecule essential for maintaining its structure. This specific mechanism results in a fungistatic action that halts the growth and reproduction of the fungal population, allowing the body to recover.

What side effects are possible with Micetal?

Possible Side Effects and Safety Information

The safety profile for Micetal (Flutrimazole) is primarily defined by its topical route of administration and low systemic absorption, as documented in regulatory-aligned safety assessments. As an azole derivative, its adverse reactions are generally localized to the application site.

Adverse Reaction Classification

Adverse reactions are classified according to frequency, using regulatory standards such as the ICH frequency bands. For Micetal, local effects are typically categorized as Common, meaning they are expected to occur in 1% to less than 10% of patients receiving the medication.

Classification	System-Organ Class	Specific Reactions (Common)
Common	Skin and Subcutaneous Tissue Disorders	Burning sensation, Erythema (redness), Pruritus (itching), Local irritation
Common	General Disorders and Administration Site Conditions	Reactions localized to the application site

Safety Characteristics and Constraints

Adverse events, when they are reported, are generally described in the safety profile as fast transient, which means the reactions are short-lived. This observation aligns with the drug's key safety constraint of low systemic absorption, which minimizes the potential for systemic exposure and subsequent systemic adverse reactions. The official safety documentation does not list specific serious adverse reactions for the topical formulation, and no specific systemic safety statements are routinely provided for special populations, such as those with hepatic or renal impairment, due to the minimal systemic bioavailability of the product.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Micetal (Flutrimazole), a topical azole antifungal, defines specific actions required in overdose situations. The risk of systemic overdose following the intended topical application is considered unlikely to be life-threatening due to the minimal dermal absorption of the active ingredient.

Exposure Scenario	Documented Manifestations	Required Emergency Action
Accidental Oral Ingestion	Systemic effects may present, including transient dizziness, nausea, and vomiting.	Seek immediate medical attention and contact a poison control center immediately.
Excessive Topical Use	Exaggerated local reactions, such as increased irritation, redness, or burning sensation at the site.	Discontinuation of treatment is required.

Regulatory Treatment and Monitoring

In the event of accidental oral ingestion, treatment is primarily symptomatic and supportive. Regulatory guidance indicates that procedural steps like gastric lavage should be considered only if clinical symptoms become apparent. No specific antidote for Flutrimazole overdose is known. Hospital monitoring may be indicated, especially for pediatric patients, who are noted as potentially having an increased risk of systemic effects following accidental oral intake. All actions are based strictly on official regulatory prescribing information.

Therapeutic Uses of Micetal

What Micetal Treats: Main Uses and Benefits

Micetal (Flutrimazole) is commonly used to help manage superficial mycoses, which are fungal infections localized to the skin's outer layers. The medication is applied in scenarios where additional management of discomfort is required, providing supportive relief which may assist with maintaining functional stability.

The medication is commonly used for conditions eligible for topical treatment exclusively, which aligns with the primary therapeutic area addressed by the medication.

The topical agent is relevant across conditions characterized by fungal and yeast-related episodic manifestations, including common tinea infections (such as athlete's foot, ringworm of the body, and jock itch), cutaneous candidiasis, and Pityriasis Versicolor.

This focused application is commonly used to help with symptom clusters that may become intense or disruptive, specifically targeting the sensations of itching (pruritus), burning, and redness associated with inflammatory or irritative states. This symptomatic relief may contribute to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress when discomfort is more noticeable.

Quick Fact: Symptomatic Support for Itching and Irritation

Eligibility and Restrictions for Use

Who can and cannot use Micetal (Flutrimazole)?

Micetal is an azole antifungal agent with officially documented eligibility criteria based on patient population, age, and physiological status. These rules define who is allowed to use the medicine under standard conditions and who must avoid it.

Contraindicated and Restricted Populations

Micetal is contraindicated for individuals with known hypersensitivity to the active substance, Flutrimazole, or to other related imidazole antifungals and excipients in the formulation. Use is also strictly prohibited in children under 10 years of age as safety and efficacy have not been established in this group.

Population Status	Regulatory Rule
Allowed	Adults and children 10 years of age and older.
Contraindicated	Children under 10 years of age; Hypersensitivity to active substance.
Restricted/Conditional	Pregnancy and Lactation (generally contraindicated, with conditional use in the first trimester only if essential).

Comorbidity and Use Limitations

Eligibility is limited by the route of administration; the medicine is only for cutaneous (topical) use and must not be applied to the eyes or mucous membranes. Regulatory documents do not impose specific restrictions based on systemic organ functions, such as hepatic or renal impairment, consistent with its topical use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for topical Flutrimazole (Micetal) confirms a minimal risk of systemic drug-drug interactions due to its limited transdermal absorption. This assessment is based on the drug's application method, which results in negligible plasma concentrations and minimal potential for systemic interference.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	None documented.
Specific interacting medicines	None explicitly listed in official regulatory documents.
Mechanistic basis of interactions	No systemic pharmacokinetic (e.g., CYP-mediated) or pharmacodynamic interaction mechanisms are documented as clinically relevant.
Timing-based interaction rules	No mandatory timing or separation requirements with systemic medications are documented.
Interaction-related restrictions	No formal restrictions on co-administration with systemic medicinal products, food, or alcohol are documented.

Interaction Classifications (High-Level)

Category	Official Regulatory Statement
Interaction severity classification	Not applicable. No interactions are formally classified as contraindicated, severe, or clinically significant.
Regulatory basis	The basis is the negligible systemic exposure of the topical formulation.
Interaction-context constraints	Interaction potential is constrained by the drug's limited transdermal absorption following topical application.

Resulting Interaction Structure

Official regulatory documents define the product's interaction structure based on its topical application, confirming that systemic exposure is minimal. The product's official interaction profile does not include formal prohibitions or specific lists of interacting substances related to metabolic pathways or drug transporters. This lack of documented systemic interaction risk is consistently reflected across authoritative government sources.

Mechanism of Action

Micetal's mechanism is defined by the direct inhibition of the fungal enzyme lanosterol 14alpha-demethylase (CYP51). This action blocks a crucial step in the ergosterol biosynthesis pathway, which is vital for fungal cellular structure. The immediate consequence of this molecular targeting is the failure to produce ergosterol, the key sterol required for fungal plasma membrane structure and function.

This depletion of ergosterol is coupled with the accumulation of toxic intermediate sterols, such as 14alpha-methyl sterols, within the fungal structure. The incorporation of these abnormal sterols severely compromises the cell membrane's integrity, fluidity, and permeability, which is the physiological change that impairs the pathogen's ability to maintain cellular function.

This structural and functional collapse of the cell membrane, caused by the dual mechanisms of ergosterol depletion and toxic sterol accumulation, results in the final physiological effect: the arrest of fungal growth and replication (fungistasis) or, at higher local concentrations, direct cell death (fungicidal action). This focused mechanistic interference controls the proliferation of the fungal population.

Dosage and Administration Information

How to Use Micetal (Flutrimazole)

Micetal is a medication intended exclusively for topical, external use and is available in several high-level dosage forms, including a 1% Cream and a 1% Gel. The choice of form and the corresponding dosing regimen are determined by the application site.

Administration and Dosage Regimens

Administration schedules vary based on the specific formulation being used:

Dosage Form	Frequency and Duration Pattern	Application Method Principle
Cream (1%)	Applied once a day for a course duration typically between 2 to 4 weeks.	Applied with a gentle massage to cover the entire affected area and adjacent skin.
Gel (1%)	Applied three times per week for a fixed period of 4 weeks (for conditions like seborrhoeic dermatitis).	Applied with friction or massage and must remain on the skin for 3 to 5 minutes before rinsing.

Use Protocol and Age Restrictions

The official protocol dictates a precise approach to application. The medication should not be applied to the eyes or mucous membranes, and use of occlusive dressings (non-breathable bandages) over the treated area is contraindicated in the context of administration.

Micetal is formally authorized for use in adults and children over 10 years of age. Usage in children younger than 10 is not established and is generally restricted by the label. The treatment course, once initiated, should be completed in full, even if the appearance of the skin improves before the prescribed duration is reached.

Recent Clinical Evidence

Research evidence / Overview of Studies for Micetal (Flutrimazole)

Evidence for Use in Tinea Pedis (Athlete's Foot)

The research base for Flutrimazole in Tinea Pedis (athlete's foot) includes randomized controlled trials (RCTs). These studies were designed to explore how Flutrimazole was studied for comparison against other topical antifungal treatments or, in some cases, an inactive product. Researchers mainly focused on adults who had confirmed fungal infections of the foot.

The trials monitored two key outcomes: mycological cure (a laboratory confirmation that the fungal organism was no longer present) and clinical cure (the assessment of changes in symptoms such as redness, peeling, and cracking). Studies also monitored changes measured during the study period related to patient-reported outcomes describing perceived discomfort. Research provides insight into short-term changes observed during the defined time intervals of the study.

Evidence for Use in General Fungal Skin Infections (Dermatomycoses)

Flutrimazole was studied for the broader category of Dermatomycoses, which includes various superficial fungal infections of the skin. Research examined a mixed group of patients with conditions caused by different dermatophytes and yeasts. The studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states.

Research in Other Localized Mycoses (Candidiasis and Pityriasis Versicolor)

For specific conditions like cutaneous candidiasis and Pityriasis Versicolor, evidence often comes from subgroup analyses within larger trials rather than dedicated large-scale studies. The studies monitored outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states.

Long-Term Studies and Follow-up

The majority of clinical trials for Micetal were focused on short-term outcomes, typically tracking patients for the duration of the 2- to 4-week treatment period, with some post-treatment follow-up extending to about one month later. There is limited information for long-term outcomes.

Evidence Gaps in Specific Populations

Most of the available research on Flutrimazole was conducted on adult populations. Data for certain groups remain insufficient. For instance, there is limited information concerning the use of Micetal in children or adolescents. The results apply only to the populations studied, meaning that research does not determine whether a similar pattern will be observed for an individual in a special population, as dedicated studies on these specific subgroups are generally lacking.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Micetal (FAQ)

Q: Is there any information about using Micetal during pregnancy or while breastfeeding?

According to official regulatory documents, the use of Micetal during pregnancy and lactation is generally considered contraindicated, meaning it should usually be avoided. Conditional use is described, noting that in the first trimester, use is generally restricted unless application is considered essential.

Q: Are there any specific foods or drinks that should be avoided when using Micetal?

Official regulatory documents state that there are no formal restrictions documented regarding co-administration with specific foods or drinks, including alcohol. This is because Micetal is for topical use (applied to the skin), and its minimal absorption into the bloodstream reduces the potential for interaction with substances that are consumed.

Q: Does Micetal cause drowsiness or affect my ability to drive?

The safety profile for topical Micetal is defined by its very low systemic absorption, meaning only negligible amounts enter the general bloodstream. For this reason, official documentation does not list systemic effects such as drowsiness or the impairment of the ability to drive in the common adverse reaction categories.

Q: Is it common to feel mild nausea when starting Micetal?

Micetal is a topical drug, and its official safety documentation primarily lists adverse reactions that are localized to the application site, such as irritation, burning sensation, and redness. Systemic reactions like nausea are not listed in the defined common side effect frequencies due to the product's minimal systemic bioavailability.

Q: Are there any known interactions between Micetal and birth control pills?

The official regulatory profile for topical Micetal indicates a minimal risk of systemic drug-drug interactions. Because the drug is applied to the skin and has limited absorption, it results in negligible levels in the bloodstream, minimizing the potential for systemic interference with other medications, including birth control pills.

Q: Are allergic reactions to Micetal common?

Micetal is formally contraindicated for individuals with known hypersensitivity to the active substance or other ingredients. The drug is classified as an azole antifungal. While the safety profile notes common local irritation effects, it does not categorize the frequency of systemic allergic reactions.

Q: Does Micetal interact with vitamins or herbal supplements?

Official documents define the drug's safety profile based on its minimal systemic exposure following topical application. No formal prohibitions or specific lists of interacting substances related to metabolic pathways are documented, which includes substances like vitamins and herbal supplements.

Q: Can I take Micetal if I have a pre-existing heart condition?

Regulatory documents generally do not impose specific restrictions based on systemic organ functions, such as hepatic, renal, or heart impairment. This aligns with the regulatory profile, which is based on the topical product’s minimal systemic exposure.

Q: Can Micetal be used alongside common antibiotics?

Official regulatory documents confirm that no specific interacting medicines are explicitly listed, and no formal restrictions on co-administration with systemic medicinal products, such as common antibiotics, are documented. This is based on the topical product’s minimal systemic exposure.

How should Micetal be stored and disposed of?

How to Store and Dispose of Micetal

Official regulatory documents define specific requirements for storing and disposing of Micetal (Flutrimazole) to maintain product stability and safety.

Storage Requirements

Requirement	Description
Temperature	Store the cream formulation at a temperature not exceeding 25 C.
Protection	Keep the container tightly closed and in a dry place to prevent moisture exposure.
Safety	The product must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Micetal must be disposed of according to local regulations. You should follow any specific disposal instructions provided on the medicine's labeling or utilize community drug take-back programs. Do not flush the medicine down a sink or toilet unless explicitly instructed to do so by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.